IRCCS Humanitas Research Hospital & Humanitas University
Published May 11, 2026 | Version v1
Other Restricted

Dataset related to article: "The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment"

Authors/Creators

  • 1. Department of Biomedical Sciences, Humanitas University, Milano, Italy
  • 2. Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland
  • 3. Department of Health Science and Technology, Swiss Federal Institute of Technology (ETH Zürich), Zurich, Switzerland
  • 4. Department of Informatics, Systems and Communication of the University of Milan-Bicocca, Milan, Italy
  • 5. Adaptive Immunity Lab, IRCCS Humanitas Research Hospital, Milan, Italy
  • 6. Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy
  • 7. Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
  • 8. Department of Pathology, IRCCS Humanitas Research Hospital, Milan, Italy,
  • 9. Institute of Genetics and Biomedical Research, UoS of Milan, National Research Council, Milan, Italy
  • 10. Institute of Molecular Bioimaging and Physiology, Consiglio Nazionale delle Ricerche (IBFM-CNR), Milan, Italy,
  • 11. Bicocca Bioinformatics, Biostatistic, Bioimaging Centre (B4), Università degli Studi di Milano-Bicocca, Milan, Italy

Description

This record contains raw data related to article “The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment”.

Abstract

Checkpoint blockade therapy (CBT) involving anti-PD1 antibodies represents the standard approach for cHL patients who do not respond to second-line therapy. Nonetheless, only 20% of relapsed/refractory (R/R) cHL patients treated with CBT achieve complete remission. In this study, we extensively examined the immune dynamics in eight R/R cHL patients treated with CBT, consisting of four complete responders (CR) and four experiencing disease progression (PD), by single cell analysis of peripheral blood mononuclear cells (PBMCs). Our unique approach encompassed longitudinal analysis with three time points, providing a comprehensive understanding of the evolving immune responses during anti-PD1 therapy. Through gene expression profiling, we identified a stable and distinctive KLRG1+/FOS+/JUN+/GZMA+/CD8+ T cell phenotype in patients achieving complete responses. This specific CD8+ T cell subset exhibited sustained activation, underscoring its potential pivotal role in mounting an effective immune response against cHL. Furthermore, T cell receptor (TCR) analysis revealed that in responder patients there is clonal expansion between TCR clonotypes specifically in the KLRG1+/FOS+/JUN+/GZMA+/CD8+ T cell subset. Our longitudinal study offers unique insights into the complex immune dynamics of multiply relapsed/highly pre-treated cHL patients undergoing anti-PD1 therapy.

Files

Restricted

The record is publicly accessible, but files are restricted. <a href="https://zenodo.org/account/settings/login?next=https://zenodo.org/records/20118352">Log in</a> to check if you have access.

Additional details

Related works

Is supplemented by
Publication: 10.3389/fonc.2025.1518107 (DOI)
Publication: 40182035 (PMID)